HIGHLIGHTS
- who: Delta variant and colleagues from the Medical Center, Republic of Korea have published the research: Journal Pre-proof, in the Journal: (JOURNAL) of 25/02/2022
- what: The primary study objective was to evaluate the clinical efficacy of regdanvimab, as determined by the proportion of patients deteriorating with SpO2 and amp;lt;90% in room air, requiring supplemental oxygen therapy above high flow, or experiencing mortality due to COVID-19 up to Day 28 in the overall cohort and in those infected with the Delta variant. The results of the study showed similar reduction . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.